FindTrial
Sign In

Expression and significance of SEMA5A in primary hepatocellular carcinoma

Expression and significance of SEMA5A in primary hepatocellular carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-COC-17013444
Enrollment
Unknown
Registered
2017-11-19
Start date
2018-01-01
Completion date
Unknown
Last updated
2017-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary hepatocellular carcinoma

Interventions

Case series:none

Sponsors

Department of Gastroenterology, The Third Affiliated Hospital of Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed as hepatocellular Carcinoma and received tumor resection in our hospital from July 2011 to June 2016 with complete information; 2. Patients diagnosed as hepatocellular Carcinoma and received tumor resection in our hospital from August 2017 to March 2018 with complete information.

Exclusion criteria

Exclusion criteria: 1. Patients with serious cardiovascular, lung, kidney, immune and hematological diseases and cerebrovascular disease; 2. Patients with severe acute infections or those with psychiatry issues; 3. Patients who refused to consent to this study.

Design outcomes

Primary

MeasureTime frame
semaphorin 5A;—

Countries

China

Contacts

Public ContactYunwei Guo

Department of Gastroenterology, The Third Affiliated Hospital of Sun Yat-sen University

guoyw1973@hotmail.com+86 13556035810

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026